## Robert J C Steele

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9215681/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Mathematical Modelling of Tumour Invasion and Metastasis. Journal of Theoretical Medicine, 2000, 2, 129-154.	0.5	238
2	A review of sex-related differences in colorectal cancer incidence, screening uptake, routes to diagnosis, cancer stage and survival in the UK. BMC Cancer, 2018, 18, 906.	2.6	214
3	Results from the first three rounds of the Scottish demonstration pilot of FOBT screening for colorectal cancer. Gut, 2009, 58, 530-535.	12.1	152
4	Overexpression and poly-ubiquitylation of the DEAD-box RNA helicase p68 in colorectal tumours. Oncogene, 2001, 20, 7734-7743.	5.9	134
5	Interval cancers in a FOBT-based colorectal cancer population screening programme: implications for stage, gender and tumour site. Gut, 2012, 61, 576-581.	12.1	131
6	The impact of a bodyweight and physical activity intervention (BeWEL) initiated through a national colorectal cancer screening programme: randomised controlled trial. BMJ, The, 2014, 348, g1823-g1823.	6.0	87
7	Effect of Gender, Age and Deprivation on Key Performance Indicators in a Fobt-based Colorectal Screening Programme. Journal of Medical Screening, 2010, 17, 68-74.	2.3	85
8	Rubber band ligation versus excisional haemorrhoidectomy for haemorrhoids. The Cochrane Library, 2005, , CD005034.	2.8	77
9	Faecal haemoglobin concentration is related to severity of colorectal neoplasia. Journal of Clinical Pathology, 2013, 66, 415-419.	2.0	77
10	Faecal haemoglobin concentrations by gender and age: implications for population-based screening for colorectal cancer. Clinical Chemistry and Laboratory Medicine, 2012, 50, 935-40.	2.3	74
11	Immunochemical testing of individuals positive for guaiac faecal occult blood test in a screening programme for colorectal cancer: an observational study. Lancet Oncology, The, 2006, 7, 127-131.	10.7	71
12	The impact of population-based faecal occult blood test screening on colorectal cancer mortality: a matched cohort study. British Journal of Cancer, 2012, 107, 255-259.	6.4	69
13	Impact of introducing a faecal immunochemical test (FIT) for haemoglobin into primary care on the outcome of patients with new bowel symptoms: a prospective cohort study. BMJ Open Gastroenterology, 2019, 6, e000293.	2.7	68
14	Clinical outcomes using a faecal immunochemical test for haemoglobin as a firstâ€line test in a national programme constrained by colonoscopy capacity. United European Gastroenterology Journal, 2013, 1, 198-205.	3.8	66
15	Effect of repeated invitations on uptake of colorectal cancer screening using faecal occult blood testing: analysis of prevalence and incidence screening. BMJ: British Medical Journal, 2010, 341, c5531-c5531.	2.3	65
16	"lt makes you feel so full of life―LiveWell, a feasibility study of a personalised lifestyle programme for colorectal cancer survivors. Supportive Care in Cancer, 2010, 18, 409-415.	2.2	62
17	MicroRNA-224 is associated with colorectal cancer progression and response to 5-fluorouracil-based chemotherapy by KRAS-dependent and -independent mechanisms. British Journal of Cancer, 2015, 112, 1480-1490.	6.4	62
18	The fecal hemoglobin concentration, age and sex test score: Development and external validation of a simple prediction tool for colorectal cancer detection in symptomatic patients. International Journal of Cancer, 2017, 140, 2201-2211.	5.1	61

#	Article	IF	CITATIONS
19	Pre-notification Increases Uptake of Colorectal Cancer Screening in All Demographic Groups: A Randomized Controlled Trial. Journal of Medical Screening, 2011, 18, 24-29.	2.3	60
20	Prehabilitation is feasible in patients with rectal cancer undergoing neoadjuvant chemoradiotherapy and may minimize physical deterioration: results from the REx trial. Colorectal Disease, 2019, 21, 548-562.	1.4	60
21	A demonstration pilot trial for colorectal cancer screening in the United Kingdom: a new concept in the introduction of healthcare strategies. Journal of Medical Screening, 2001, 8, 197-203.	2.3	57
22	Back-to-back colon capsule endoscopy and optical colonoscopy in colorectal cancer screening individuals. Colorectal Disease, 2018, 20, 479-485.	1.4	53
23	Anticipated regret to increase uptake of colorectal cancer screening (ARTICS): A randomised controlled trial. Social Science and Medicine, 2015, 142, 118-127.	3.8	52
24	Impact of the UK colorectal cancer screening pilot studies on incidence, stage distribution and mortality trends. Cancer Epidemiology, 2012, 36, e232-e242.	1.9	50
25	Use of a faecal immunochemical test narrows current gaps in uptake for sex, age and deprivation in a bowel cancer screening programme. Journal of Medical Screening, 2013, 20, 80-85.	2.3	50
26	p53 in cancer: A paradigm for modern management of cancer. Journal of the Royal College of Surgeons of Edinburgh, 2005, 3, 197-205.	1.8	46
27	Obesity and lifestyle advice in colorectal cancer survivors – how well are clinicians prepared?. Colorectal Disease, 2013, 15, 949-957.	1.4	42
28	Faecal immunochemical testing (FIT) in patients with signs or symptoms of suspected colorectal cancer (CRC): a joint guideline from the Association of Coloproctology of Great Britain and Ireland (ACPGBI) and the British Society of Gastroenterology (BSG). Gut, 2022, 71, 1939-1962.	12.1	41
29	Occult blood in faeces is associated with all-cause and non-colorectal cancer mortality. Gut, 2018, 67, 2116-2123.	12.1	40
30	Interval cancers using a quantitative faecal immunochemical test (FIT) for haemoglobin when colonoscopy capacity is limited. Journal of Medical Screening, 2016, 23, 130-134.	2.3	38
31	Experience with a two-tier reflex gFOBT/FIT strategy in a national bowel screening programme. Journal of Medical Screening, 2012, 19, 8-13.	2.3	33
32	Should we use total mortality rather than cancer specific mortality to judge cancer screening programmes? No. BMJ: British Medical Journal, 2011, 343, d6397-d6397.	2.3	32
33	Transition to quantitative faecal immunochemical testing from guaiac faecal occult blood testing in a fully rolled-out population-based national bowel screening programme. Gut, 2021, 70, 106-113.	12.1	31
34	Deprivation and faecal haemoglobin: implications for bowel cancer screening. Journal of Medical Screening, 2014, 21, 95-97.	2.3	29
35	Does prehabilitation modify muscle mass in patients with rectal cancer undergoing neoadjuvant therapy? A subanalysis from the REx randomised controlled trial. Techniques in Coloproctology, 2020, 24, 959-964.	1.8	29
36	Patterns of uptake in a biennial faecal occult blood test screening programme for colorectal cancer. Colorectal Disease, 2014, 16, 28-32.	1.4	28

#	Article	IF	CITATIONS
37	Comparing uptake across breast, cervical and bowel screening at an individual level: a retrospective cohort study. British Journal of Cancer, 2019, 121, 710-714.	6.4	28
38	Ultrasound capsule endoscopy: sounding out the future. Annals of Translational Medicine, 2017, 5, 201-201.	1.7	28
39	Colorectal cancer screening – Methodology. Journal of the Royal College of Surgeons of Edinburgh, 2010, 8, 164-171.	1.8	27
40	Study protocol for BeWEL: The impact of a BodyWEight and physicaL activity intervention on adults at risk of developing colorectal adenomas. BMC Public Health, 2011, 11, 184.	2.9	27
41	Socioeconomic Variation and Prostate Specific Antigen Testing in the Community: A United Kingdom Based Population Study. Journal of Urology, 2013, 190, 1207-1212.	0.4	27
42	Feasibility study to assess the impact of a lifestyle intervention (â€~LivingWELL') in people having an assessment of their family history of colorectal or breast cancer. BMJ Open, 2018, 8, e019410.	1.9	27
43	Are there ethnic and religious variations in uptake of bowel cancer screening? A retrospective cohort study among 1.7 million people in Scotland. BMJ Open, 2020, 10, e037011.	1.9	25
44	European guidelines for quality assurance in colorectal cancer screening and diagnosis. First Edition – Management of lesions detected in colorectal cancer screening. Endoscopy, 2012, 44, SE140-SE150.	1.8	24
45	Recommendations for a stepâ€wise comparative approach to the evaluation of new screening tests for colorectal cancer. Cancer, 2016, 122, 826-839.	4.1	24
46	Yield of colorectal cancer at colonoscopy according to faecal haemoglobin concentration in symptomatic patients referred from primary care. Colorectal Disease, 2021, 23, 1615-1621.	1.4	24
47	Uptake trends in the Scottish Bowel Screening Programme and the influences of age, sex, and deprivation. Journal of Medical Screening, 2018, 25, 24-31.	2.3	23
48	Why colorectal screening fails to achieve the uptake rates of breast and cervical cancer screening: a comparative qualitative study. BMJ Quality and Safety, 2020, 29, 482-490.	3.7	22
49	p53 as a therapeutic target. Journal of the Royal College of Surgeons of Edinburgh, 2008, 6, 240-243.	1.8	21
50	Malignancy within a Tail Gut Cyst: A Case of Retrorectal Carcinoid Tumour. Case Reports in Surgery, 2014, 2014, 1-4.	0.4	20
51	Faecal haemoglobin distributions by sex, age, deprivation and geographical region: consequences for colorectal cancer screening strategies. Clinical Chemistry and Laboratory Medicine, 2020, 58, 2073-2080.	2.3	20
52	Automated immunochemical quantitation of haemoglobin in faeces collected on cards for screening for colorectal cancer. Gut, 2008, 57, 1256-1260.	12.1	19
53	Health Behaviors and their Relationship with Disease Control in People Attending Genetic Clinics with a Family History of Breast or Colorectal Cancer. Journal of Genetic Counseling, 2017, 26, 40-51. 	1.6	19
54	Why are some people more successful at lifestyle change than others? Factors associated with successful weight loss in the BeWEL randomised controlled trial of adults at risk of colorectal cancer. International Journal of Behavioral Nutrition and Physical Activity, 2015, 12, 87.	4.6	17

#	Article	IF	CITATIONS
55	Faecal haemoglobin concentration is related to detection of advanced colorectal neoplasia in the next screening round. Journal of Medical Screening, 2017, 24, 62-68.	2.3	17
56	Telephone assessment increases uptake of colonoscopy in a FOBT colorectal cancer-screening programme. Journal of Medical Screening, 2008, 15, 105-107.	2.3	16
57	The contribution of a negative colorectal screening test result to symptom appraisal and helpâ€seeking behaviour among patients subsequently diagnosed with an interval colorectal cancer. Health Expectations, 2018, 21, 764-773.	2.6	16
58	Anticipated regret to increase uptake of colorectal cancer screening in Scotland (ARTICS): study protocol for a randomised controlled trial. BMC Public Health, 2013, 13, 849.	2.9	15
59	Interval cancers in a national colorectal cancer screening programme. United European Gastroenterology Journal, 2016, 4, 587-594.	3.8	15
60	Faecal haemoglobin can define risk of colorectal neoplasia at surveillance colonoscopy in patients at increased risk of colorectal cancer. United European Gastroenterology Journal, 2020, 8, 559-566.	3.8	15
61	Faecal haemoglobin concentration thresholds for reassurance and urgent investigation for colorectal cancer based on a faecal immunochemical test in symptomatic patients in primary care. Annals of Clinical Biochemistry, 2021, 58, 211-219.	1.6	15
62	Methods and Economic Considerations: Group 1 Report. Endoscopy, 2004, 36, 349-353.	1.8	13
63	Measurement of faecal haemoglobin with a faecal immunochemical test can assist in defining which patients attending primary care with rectal bleeding require urgent referral. Annals of Clinical Biochemistry, 2020, 57, 325-327.	1.6	13
64	Faecal Haemoglobin Estimated by Faecal Immunochemical Tests—An Indicator of Systemic Inflammation with Real Clinical Potential. Diagnostics, 2021, 11, 2093.	2.6	13
65	Do other variables add value to assessment of the risk of colorectal disease using faecal immunochemical tests for haemoglobin?. Annals of Clinical Biochemistry, 2019, 56, 472-479.	1.6	12
66	The Psychological Impact of a Colorectal Cancer Diagnosis Following a Negative Fecal Occult Blood Test Result. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1032-1038.	2.5	10
67	Feasibility study to assess the delivery of a lifestyle intervention (TreatWELL) for patients with colorectal cancer undergoing potentially curative treatment. BMJ Open, 2018, 8, e021117.	1.9	10
68	European guidelines for quality assurance in colorectal cancer screening and diagnosis. First Edition – Professional requirements and training. Endoscopy, 2012, 44, SE106-SE115.	1.8	9
69	Impact of faecal occult blood test screening on emergency admissions and short-term outcomes for colorectal cancer. British Journal of Surgery, 2014, 101, 1607-1615.	0.3	8
70	Reproducibility and accuracy of visual estimation of polyp size in large colorectal polyps. Acta Oncológica, 2019, 58, S37-S41.	1.8	8
71	Cause of Death, Mortality and Occult Blood in Colorectal Cancer Screening. Cancers, 2022, 14, 246.	3.7	8
72	Understanding of a negative bowel screening result and potential impact on future symptom appraisal and helpâ€seeking behaviour: a focus group study. Health Expectations, 2017, 20, 584-592.	2.6	7

#	Article	IF	CITATIONS
73	Is an opportunistic primary care-based intervention for non-responders to bowel screening feasible and acceptable? A mixed-methods feasibility study in Scotland. BMJ Open, 2017, 7, e016307.	1.9	7
74	Strategies to minimise the current disadvantages experienced by women in faecal immunochemical test-based colorectal cancer screening. Clinical Chemistry and Laboratory Medicine, 2022, 60, 1496-1505.	2.3	7
75	Negative screening colonoscopy after a positive guaiac faecal occult blood test: not a contraindication to continued screening. Colorectal Disease, 2012, 14, 943-946.	1.4	6
76	Participation in bowel screening among men attending abdominal aortic aneurysm screening. British Journal of Surgery, 2018, 105, 529-534.	0.3	6
77	Lifestyle in patients at increased risk of colorectal cancer. Journal of Human Nutrition and Dietetics, 2019, 32, 570-577.	2.5	6
78	Making sense of bodily sensations: Do shared cancer narratives influence symptom appraisal?. Social Science and Medicine, 2019, 223, 31-39.	3.8	6
79	Variation in changes in the incidence of colorectal cancer by age and association with screening uptake: an observational study. BMJ Open, 2020, 10, e037925.	1.9	6
80	Faecal haemoglobin concentrations in women and men diagnosed with colorectal cancer in a national screening programme. Journal of Medical Screening, 2022, 29, 26-31.	2.3	6
81	Can the performance of a quantitative FIT-based colorectal cancer screening programme be enhanced by lowering the threshold and increasing the interval?. Gut, 2018, 67, 993-994.	12.1	5
82	Randomized controlled trial: Flexible sigmoidoscopy as an adjunct to faecal occult blood testing in population screening. Journal of Medical Screening, 2020, 27, 59-67.	2.3	5
83	Modern challenges in colorectal cancer. Journal of the Royal College of Surgeons of Edinburgh, 2006, 4, 285-291.	1.8	4
84	e-Science and artificial neural networks in cancer management. Concurrency Computation Practice and Experience, 2007, 19, 251-263.	2.2	4
85	The impact of personalised risk information compared to a positive/negative result on informed choice and intention to undergo colonoscopy following colorectal Cancer screening in Scotland (PERICCS) - a randomised controlled trial: study protocol. BMC Public Health, 2019, 19, 411.	2.9	4
86	Association between faecal occult bleeding and medicines prescribed for chronic disease: a data linkage study. Journal of Clinical Pathology, 2021, 74, 664-667.	2.0	4
87	Colorectal cancer screening. British Journal of Surgery, 2014, 101, 1338-1340.	0.3	3
88	Overview of colorectal cancer screening. Colorectal Disease, 2019, 21, 14-15.	1.4	3
89	Colorectal cancer screening participation: Exploring relationship heterogeneity and scale differences using multiscale geographically weighted regression. Geospatial Health, 2021, 16, .	0.8	3
90	Colorectal adenomas and diabetes: implications for disease prevention. Colorectal Disease, 2015, 17, 589-594.	1.4	2

#	Article	IF	CITATIONS
91	Changes in prevalence of faecal occult blood positivity over time. Journal of Medical Screening, 2019, 26, 191-196.	2.3	2
92	Low Sensitivity of Fecal Immunochemical Tests (FIT) for Detection of Sessile Serrated Adenomas/Polyps Confirmed Over Clinical Setting, Geography, and FIT System. Digestive Diseases and Sciences, 2019, 64, 3024-3026.	2.3	2
93	Anastomotic recurrence of rectal adenoma after anterior resection. Surgical Endoscopy and Other Interventional Techniques, 2003, 17, 1851-1851.	2.4	1
94	Colorectal Cancer Screening in Scotland. Zeitschrift Fur Gastroenterologie, 2008, 46, 33-34.	0.5	1
95	Critical considerations of fecal occult blood tests for colorectal cancer. Colorectal Cancer, 2013, 2, 1-3.	0.8	1
96	The impact of hypothetical PErsonalised Risk Information on informed choice and intention to undergo Colorectal Cancer screening colonoscopy in Scotland (PERICCS)—a randomised controlled trial. BMC Medicine, 2020, 18, 285.	5.5	1
97	Genetics for surgeons. P. J. Morrison and R. A. J. Spence. 147 × 210 mm. Pp. 223. Illustrated. 2005. Remidica: London. £20. British Journal of Surgery, 2005, 92, 785-785.	0.3	0
98	Prioritisation of referrals. Journal of the Royal College of Surgeons of Edinburgh, 2008, 6, 132.	1.8	0
99	Experience with a wipe guaiac-based faecal occult blood test as an alternative test in a bowel screening programme. Journal of Medical Screening, 2010, 17, 211-213.	2.3	0
100	Commentary: Reply to â€~Accrediting colonoscopy services and colonoscopists for screening makes a difference'. Colorectal Disease, 2018, 20, O285.	1.4	0